Literature DB >> 18437332

Aldosterone in salt-sensitive hypertension and metabolic syndrome.

Toshiro Fujita1.   

Abstract

Metabolic syndrome, which is caused by obesity, is now a global pandemic. Metabolic syndrome is an aggregation of hypertension, diabetes and dyslipidaemia. Insulin resistance is a key factor in the development of these components of metabolic syndrome. Concerning the mechanism for the development of hypertension in metabolic syndrome, the lack of insulin resistance in the kidney increases sodium reabsorption by hyperinsulinaemia, leading to sodium retention in the body, and resultant salt-sensitive hypertension. Moreover, hyperaldosteronism, which is caused by adipocyte-derived aldosterone-releasing factors, induces not only salt-sensitive hypertension, but also proteinuria in obese hypertensive rats. Salt loading markedly aggravates proteinuria and induces cardiac diastolic dysfunction in obese hypertensive rats, suggesting that salt and aldosterone exert unfavourable synergistic actions on the cardiovascular system, possibly through the overproduction of oxidative stress. In turn, reactive oxygen species (ROS), which are induced by adipokines such as tumour necrosis factor-alpha, non-esterified fatty acids, angiotensinogen etc., can activate the mineralocorticoid (MR) receptor, in an aldosterone-independent fashion. Therefore, aldosterone/MR activation plays a key role not only in the development of salt-sensitive hypertension, but also in cardiovascular injury in metabolic syndrome, possibly through its function as a feed-forward system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437332     DOI: 10.1007/s00109-008-0343-1

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  33 in total

1.  Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling.

Authors:  Takehide Ogihara; Tomoichiro Asano; Katsuyuki Ando; Yuko Chiba; Hideyuki Sakoda; Motonobu Anai; Nobuhiro Shojima; Hiraku Ono; Yukiko Onishi; Midori Fujishiro; Hideki Katagiri; Yasushi Fukushima; Masatoshi Kikuchi; Noriko Noguchi; Hiroyuki Aburatani; Issei Komuro; Toshiro Fujita
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.

Authors:  Miki Nagase; Shigeru Shibata; Shigetaka Yoshida; Takashi Nagase; Takanari Gotoda; Toshiro Fujita
Journal:  Hypertension       Date:  2006-04-24       Impact factor: 10.190

3.  Plasma aldosterone is independently associated with the metabolic syndrome.

Authors:  Murielle Bochud; Jürg Nussberger; Pascal Bovet; Marc R Maillard; Robert C Elston; Fred Paccaud; Conrad Shamlaye; Michel Burnier
Journal:  Hypertension       Date:  2006-06-19       Impact factor: 10.190

4.  Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells.

Authors:  Toru Sugiyama; Takanobu Yoshimoto; Kyoichiro Tsuchiya; Naoki Gochou; Yuki Hirono; Toru Tateno; Nozomi Fukai; Masayoshi Shichiri; Yukio Hirata
Journal:  Endocrinology       Date:  2005-06-02       Impact factor: 4.736

5.  Urinary excretion of 8-oxo-7, 8-dihydro-2'-deoxyguanosine as a predictor of the development of diabetic nephropathy.

Authors:  Y Hinokio; S Suzuki; M Hirai; C Suzuki; M Suzuki; T Toyota
Journal:  Diabetologia       Date:  2002-05-08       Impact factor: 10.122

6.  Cardiac type-1 angiotensin II receptor status in deoxycorticosterone acetate-salt hypertension in rats.

Authors:  J Fareh; R M Touyz; E L Schiffrin; G Thibault
Journal:  Hypertension       Date:  1997-11       Impact factor: 10.190

Review 7.  Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.

Authors:  Bertram Pitt
Journal:  Mol Cell Endocrinol       Date:  2004-03-31       Impact factor: 4.102

8.  Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart.

Authors:  Ricardo Rocha; Cynthia L Martin-Berger; Pochang Yang; Rachel Scherrer; John Delyani; Ellen McMahon
Journal:  Endocrinology       Date:  2002-12       Impact factor: 4.736

Review 9.  Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity.

Authors:  Claude Roberge; André C Carpentier; Marie-France Langlois; Jean-Patrice Baillargeon; Jean-Luc Ardilouze; Pierre Maheux; Nicole Gallo-Payet
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-10-02       Impact factor: 4.310

Review 10.  The new biology of aldosterone.

Authors:  John M C Connell; Eleanor Davies
Journal:  J Endocrinol       Date:  2005-07       Impact factor: 4.286

View more
  25 in total

Review 1.  Obesity and renovascular disease.

Authors:  Xin Zhang; Lilach O Lerman
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-03

2.  Modified high-density lipoprotein modulates aldosterone release through scavenger receptors via extra cellular signal-regulated kinase and Janus kinase-dependent pathways.

Authors:  Sarama Saha; Juergen Graessler; Peter E H Schwarz; Claudia Goettsch; Stefan R Bornstein; Steffi Kopprasch
Journal:  Mol Cell Biochem       Date:  2012-03-01       Impact factor: 3.396

3.  Feedforward activation of endothelial ENaC by high sodium.

Authors:  Stefanie Korte; Alexandra S Sträter; Verena Drüppel; Hans Oberleithner; Pia Jeggle; Claudia Grossmann; Manfred Fobker; Jerzy-Roch Nofer; Eva Brand; Kristina Kusche-Vihrog
Journal:  FASEB J       Date:  2014-05-27       Impact factor: 5.191

Review 4.  Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus.

Authors:  Surapon Tangvarasittichai
Journal:  World J Diabetes       Date:  2015-04-15

Review 5.  Aldosterone and arterial hypertension.

Authors:  Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Barbara Obermayer-Pietsch; Thomas R Pieber
Journal:  Nat Rev Endocrinol       Date:  2009-12-22       Impact factor: 43.330

Review 6.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

7.  VLDL-activated cell signaling pathways that stimulate adrenal cell aldosterone production.

Authors:  Ying-Ying Tsai; William E Rainey; Maribeth H Johnson; Wendy B Bollag
Journal:  Mol Cell Endocrinol       Date:  2016-05-21       Impact factor: 4.102

8.  Analysis of metabolites in plasma reveals distinct metabolic features between Dahl salt-sensitive rats and consomic SS.13(BN) rats.

Authors:  Le Wang; Entai Hou; Zhengjun Wang; Na Sun; Liqing He; Lan Chen; Mingyu Liang; Zhongmin Tian
Journal:  Biochem Biophys Res Commun       Date:  2014-06-24       Impact factor: 3.575

Review 9.  Reactive oxygen species and dopamine receptor function in essential hypertension.

Authors:  Chunyu Zeng; Van Anthony M Villar; Peiying Yu; Lin Zhou; Pedro A Jose
Journal:  Clin Exp Hypertens       Date:  2009-04       Impact factor: 1.749

10.  Effect of high fat loading in Dahl salt-sensitive rats.

Authors:  Ai Nagae; Megumi Fujita; Hiroo Kawarazaki; Hiromitu Matsui; Katsuyuki Ando; Toshiro Fujita
Journal:  Clin Exp Hypertens       Date:  2009-07       Impact factor: 1.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.